David G Menter1, Jennifer S Davis2, Bradley M Broom3, Michael J Overman4, Jeffrey Morris2, Scott Kopetz4. 1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard--Unit 0426, Houston, TX, 77030, USA. dmenter@mdanderson.org. 2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 4. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard--Unit 0426, Houston, TX, 77030, USA.
Abstract
PURPOSE OF REVIEW: This review seeks to provide an informed prospective on the advances in molecular profiling and analysis of colorectal cancer (CRC). The goal is to provide a historical context and current summary on how advances in gene and protein sequencing technology along with computer capabilities led to our current bioinformatic advances in the field. RECENT FINDINGS: An explosion of knowledge has occurred regarding genetic, epigenetic, and biochemical alterations associated with the evolution of colorectal cancer. This has led to the realization that CRC is a heterogeneous disease with molecular alterations often dictating natural history, response to treatment, and outcome. The consensus molecular subtypes (CMS) classification classifies CRC into four molecular subtypes with distinct biological characteristics, which may form the basis for clinical stratification and subtype-based targeted intervention. This review summarizes new developments of a field moving "Back to the Future." CRC molecular subtyping will better identify key subtype specific therapeutic targets and responses to therapy.
PURPOSE OF REVIEW: This review seeks to provide an informed prospective on the advances in molecular profiling and analysis of colorectal cancer (CRC). The goal is to provide a historical context and current summary on how advances in gene and protein sequencing technology along with computer capabilities led to our current bioinformatic advances in the field. RECENT FINDINGS: An explosion of knowledge has occurred regarding genetic, epigenetic, and biochemical alterations associated with the evolution of colorectal cancer. This has led to the realization that CRC is a heterogeneous disease with molecular alterations often dictating natural history, response to treatment, and outcome. The consensus molecular subtypes (CMS) classification classifies CRC into four molecular subtypes with distinct biological characteristics, which may form the basis for clinical stratification and subtype-based targeted intervention. This review summarizes new developments of a field moving "Back to the Future." CRC molecular subtyping will better identify key subtype specific therapeutic targets and responses to therapy.
Authors: S M Powell; N Zilz; Y Beazer-Barclay; T M Bryan; S R Hamilton; S N Thibodeau; B Vogelstein; K W Kinzler Journal: Nature Date: 1992-09-17 Impact factor: 49.962
Authors: K W Kinzler; M C Nilbert; L K Su; B Vogelstein; T M Bryan; D B Levy; K J Smith; A C Preisinger; P Hedge; D McKechnie Journal: Science Date: 1991-08-09 Impact factor: 47.728
Authors: Larisse Silva Dalla Libera; Thalita de Siqueira; Igor Lopes Santos; Jéssica Enocencio Porto Ramos; Amanda Xavier Milhomen; Rita de Cassia Gonçalves de Alencar; Silvia Helena Rabelo Santos; Megmar Aparecida Dos Santos Carneiro; Rosane Ribeiro Figueiredo Alves; Vera Aparecida Saddi Journal: PLoS One Date: 2020-06-25 Impact factor: 3.240
Authors: Anna-Lena Scherr; Andreas Mock; Georg Gdynia; Nathalie Schmitt; Christoph E Heilig; Felix Korell; Praveen Rhadakrishnan; Paula Hoffmeister; Klaus H Metzeler; Klaus Schulze-Osthoff; Anna L Illert; Melanie Boerries; Jörg Trojan; Oliver Waidmann; Johanna Falkenhorst; Jens Siveke; Philipp J Jost; Michael Bitzer; Nisar P Malek; Loredana Vecchione; Ivan Jelas; Benedikt Brors; Hanno Glimm; Albrecht Stenzinger; Svetlana P Grekova; Tobias Gehrig; Henning Schulze-Bergkamen; Dirk Jäger; Peter Schirmacher; Mathias Heikenwalder; Benjamin Goeppert; Martin Schneider; Stefan Fröhling; Bruno C Köhler Journal: Cell Death Dis Date: 2020-10-17 Impact factor: 8.469
Authors: Jerzy Lasota; Małgorzata Chłopek; Bartosz Wasąg; Artur Kowalik; Jason Christiansen; Jennifer Lamoureux; Alina Kuźniacka; Anna Felisiak-Gołąbek; Yalan Liu; Tiffany Ashley R Reyes; Rishabh Saha; Abbas Agaimy; Kristyna Behenska; Wojciech Biernat; Laura Cattaneo; Giovanni Centonze; Ondrej Daum; Magdalena Daumova; Paweł Domagała; Ireneusz Dziuba; Carol E Geppert; Stanisław Góźdź; Anna Nasierowska-Guttmejer; Agnieszka Hałoń; Arndt Hartmann; Shingo Inaguma; Ewa Iżycka-Świeszewska; Maciej Kaczorowski; Małgorzata Kołos; Janusz Kopczyński; Michal Michal; Massimo Milione; Krzysztof Okoń; Rafał Pęksa; Michał Pyzlak; Janusz Ryś; Piotr Waloszczyk; Jaroslaw Wejman; Markku Miettinen Journal: Am J Surg Pathol Date: 2020-09 Impact factor: 6.298
Authors: Sára Zsigrai; Alexandra Kalmár; Zsófia B Nagy; Barbara K Barták; Gábor Valcz; Krisztina A Szigeti; Orsolya Galamb; Titanilla Dankó; Anna Sebestyén; Gábor Barna; Vanessza Szabó; Orsolya Pipek; Anna Medgyes-Horváth; István Csabai; Zsolt Tulassay; Péter Igaz; István Takács; Béla Molnár Journal: Cells Date: 2020-08-09 Impact factor: 6.600